Inozyme Pharma Overview
Latest P/E ratio for Inozyme Pharma: -2.47 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-2.47
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Inozyme Pharma (INZY) currently reports a P/E ratio of -2.47. That is below the Healthcare sector average of 26.85. Use the charts on this page to explore Inozyme Pharma's P/E ratio history and peer comparisons.
Inozyme Pharma's P/E ratio of -2.47 is lower than the Healthcare sector average of 26.85. That is roughly 109.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Inozyme Pharma's market price to a fundamental measure such as earnings, sales, or book value. At -2.47, INZY can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -2.47, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Inozyme Pharma, and consider following INZY for alerts when major investors trade the stock.
Inozyme Pharma is classified in the Healthcare sector. On P/E ratio, it currently shows -2.47 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INZY with unrelated industries.
